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Introduction
Aspects in neurosurgical and neurocriti-
cal care treatment changed in the periods be-
fore 1993, between 1993 and 1999, and 
between 1999 and 2003. Before 1993, patients 
with aneurysmal subarachnoid hemorrhage 
(aSAH) World Federation of Neurosurgical 
Societies (WFNS) grade 3 and higher under-
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Introduction: To evaluate the impact of specialized neurocritical care on the population 
admitted to a neurovascular center and on the outcome of patients with severe aneurysmal 
subarachnoid hemorrhage (aSAH).
Methods: After exclusion of patients treated with endovascular techniques, between 1999 
and 2003, 198 patients with aSAH treated with early aneurysm clipping were analysed. In 
1999, a new standardized protocol for intensive care treatment was established in the 
Department of Neurosurgery, University Hospital Zurich. The results were compared to the 
earlier time period (1993–1994) immediately after introduction of early aneurysm clipping.
Results: Out of 198 patients with aSAH, 90 patients (45.5%) suffered from mild aSAH 
World Federation of Neurosurgical Societies (WFNS) grade 1 and 2, 41 (27.3%) from aSAH 
WFNS grade 3, 36 (18.2%) from grade 4, and 57 (28.8%) from grade 5. From 1999 to 2003, 
significantly more patients with severe aSAH WFNS grade 4 and 5 underwent (further) 
treatment (93 out of 198 patients; 47.0%) compared to the former time-period after 
introduction of early surgery (23 out of 150 patients; 15.3%) (p < 0.0001). In the early 
series, 10 out of 23 patients (43.5%) with WFNS 4 recovered with good outcome Glasgow 
Outcome Score 4 and 5, whereas in the later series 23 out of 36 (63.9%) with WFNS grade 
4 survived in a good functional state. Before 1999, all patients with WFNS grade 5 died 
or survived in a vegetative state. From 1999 to 2003, 20 out of 57 patients (35.1%) with 
aSAH WFNS grade 5 survived with good outcome.
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went no surgery during the acute stage (1). 
In 1993, early aneurysm surgery was estab-
lished in the Department of Neurosurgery, 
University Hospital Zurich (2). Patients with 
WFNS grade 5, however, were excluded from 
neurosurgical treatment. In 1999, a standard-
ized protocol for emergency and specialized 
neurocritical care treatment was introduced, 
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whereas the technical aspects in microneurosurgery didn’t 
change. The purpose of this report is to evaluate the impact of 
specialized neurocritical care treatment on the patient popula-
tion admitted to a specialized neurovascular center and on the 
outcome of patients with high-grade aSAH. Therefore, after 
exclusion of patients treated with endovascular techniques, 
the results from a patient series with aSAH treated with early 
aneurysm clipping between 1999 and 2003 (immediately after 
implementation of a structured neuro critical care treatment) 
are presented and compared to a former published series of 
patients, treated between 1993 and 1994 (immediately after 
implementation of early aneurysm surgery) (2).
Material and Methods
The study was approved as a part of the project E-015/99 
by the Ethics Committee of the University of Zurich. Since 
January 1999, special neurocritical care personnel have been 
available at the Department of Neurosurgery, University 
Hospital Zurich. Nursing and medical staff were educated, 
and guidelines and standards were implemented in general-
ized and specific aspects of neurocritical care. Protocols for 
treatment of elevated intracranial pressure (ICP) and detection 
and treatment of cerebral vasospasm (CVS) were established. 
For this study, data from patients treated between January 
1999 and December 2003 with aneurysm clipping within 
3 days after symptom onset were analyzed. Patients treated 
with endovascular coiling were excluded from the analysis.
Structured Treatment
Aneurysm clipping was performed according to the stan-
dard microsurgical technique described by Yasargil (1). 
Surgical techniques didn’t change between 1993 and 2003. The 
evaluation included only patients with aneurysm clipping 
within 3 days after aSAH. All patients were treated with ni-
modipine for 21 days and kept flat in bed as long as cerebral 
autoregulation, examined with transcranial Doppler (TCD), 
was defective. Dexamethasone was given perioperatively. 
Prophylactic antiepileptic treatment with valproate was initi-
ated in patients with aSAH and Hunt & Hess grade 3 and 
higher (3–6). In patients with aSAH Hunt & Hess grade 1 to 3, 
sedation was stopped immediately after surgery.
Treatment of Elevated ICP
In patients with poor-grade aSAH, emergency treatment of 
elevated ICP consisted of sedation with intubation, osmother-
apy (Mannitol 20% and hypertonic NaCl-hydroxyethyl-starch 
solution), mild hyperventilation, and thiopental boli in a dose 
of 5–10 mg/kg body weight (BW) (7). Patients with occlusive 
hydrocephalus were treated immediately with a ventricular 
probe for cerebrospinal fluid (CSF) drainage. If, in patients 
with most-severe aSAH WFNS grade 5, pupil disturbances 
normalized because of the previously mentioned treatment, 
the treatment was continued and craniotomy and aneurysm 
clipping were performed based on emergency diagnostic 
 evaluation with angiography or computed tomographic (CT) 
angiography. After early aneurysm surgery, patients with 
poor-grade aSAH and severe brain edema remained sedated. A 
ventricular catheter (NMT Neuroscience, Frankfurt, Germany) 
was inserted to provide continuous ICP monitoring and drain-
age of CSF, if necessary. If a ventricular catheter could not be 
placed in the ventricular system because of massive brain 
edema, a subdural (NMT Neuroscience) or an intraparenchy-
matous (Codman microsensor, Johnson & Johnson, Raynham) 
ICP probe was inserted. With elevated ICP (>20 mmHg) treat-
ment with intermittent CSF drainage, osmotherapy, mild hy-
perventilation (target PaCO2 values adapted to jugular bulb 
oximetry), and tris-hydroxy-methyl-aminomethane (THAM) 
buffer was initiated (8). Patients with persistant ICP values 
greater than 20 mmHg were eligible for treatment with 
 barbiturate coma combined with mild hypothermia. Medical 
therapy, barbiturate coma, and hypothermia treatment were 
performed according to a standardized algorithm for treatment 
of elevated ICP (9). Barbiturate coma was induced at the same 
time as induction of hypothermia and was adapted to a burst 
suppression pattern in continuous electroencephalogram 
(EEG) monitoring. Cooling of the patients (target brain tem-
perature 33°C) was accomplished by using cooling blankets 
(Bair Hugger, Augustine Medical, Saint Prarie, MN, and 
Blanketrol, CSZ, Cincinnatti, OH) or endovascular cooling 
catheters (Cool Line Catheter and Coolgard System; Alsius 
Corporation, Irvine, CA) (10). All patients were treated under 
extended monitoring of cerebral hemodynamics (monitoring 
of jugular bulb oxygen saturation, cerebral blood flow [CBF], 
and/or intraparenchymatous oxygen partial pressure) (11–13). 
If, after aneurysm surgery, patients developed increasing brain 
edema and elevated ICP was resistant to the previously men-
tioned conservative treatment, secondary decompressive hemi-
craniectomy combined with duraplasty was performed (14).
Detection of CVS
TCD blood flow measurements were performed daily. In 
conscious patients, symptomatic CVS was defined by the oc-
currence of delayed ischemic neurological deficit (DIND) (de-
crease in consciousness, new focal neurological deficits). After 
hypoxia, electrolyte imbalance and hydrocephalus were ex-
cluded on the basis of a further CT scan, and symptomatic 
CVS was suspected. CVS in all patients was confirmed with 
digital subtraction angiography. The role of TCD in predicting 
symptomatic CVS is limited (15). Therefore, if the neurological 
state could not be assessed properly (e.g., because of sedation 
or poor neurological grade) patients were additionally moni-
tored with jugular bulb oxymetry, lactate measurements from 
the jugular bulb (16), daily CBF measurements (near-infrared 
spectroscopy indocyanine green dye dilution method) (13), 
and/or perfusion CT examinations (17). If jugular bulb O2 de-
saturation occurred, arteriovenous difference of lactate (avDL) 
was –0.2 µmol/dL or less, CBF values decreased more than 
20%, and/or differences in territorial or hemispheric transit 
times occurred in perfusion CT, symptomatic CVS was sus-
pected and digital subtraction angiography was performed. 
Likewise, all patients with new ischemic infarctions, compared 
to the postoperative CT examination, were classified as suffer-
ing from CVS.
Treatment of CVS
Benefits of hypertensive hypervolemic hemodilution (Triple 
H) therapy have never been unequivocally  demonstrated 
by randomized controlled studies (6,18). In early studies, 
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 patients with volume expansion showed less frequent DINDs 
and better outcome compared to control patients who were 
kept dehydrated (19), whereas in more recent  studies, no effect 
of hypervolemia on either CBF or DINDs was found if control 
patients were already receiving more than 3000 mL fluids per 
day (20). Therefore, our treatment protocol didn’t foresee a 
prophylactic Triple H therapy for our patients. Before the pa-
tients developed signs of CVS, the daily fluid balance was 
aimed to be positive, adjusting the fluid intake by intravenous 
infusion of crystalloids and hydroxyethyl-starch solution 
(HES; 1000 mL/day). If signs of CVS occurred, patients were 
treated according to a multimodal structured treatment pro-
tocol based on the  results of clinical studies and personal ex-
perience (Table 1) (6,9,11,18,21–29).
Table 1 CVS Treatment Protocol
CVS, cerebral vasospasm; DIND, delayed ischemic neurological deficit; CBF, cerebral blood flow; EVLWI, extravascular lung water index; 
TCD, transcranial Doppler.
88   Lerch et al.
Neurocritical Care ♦ Volume 5, 2006
Triple H Therapy
Triple H therapy was induced if TCD mean blood flow ve-
locities increased (mean middle cerebral artery blood flow ve-
locities > 140 cm/second or increase >50 cm/second within 24 
hours). If significant differences were present in perfusion CT, 
jugular bulb O2 desaturations occurred in case of increased 
avDL, decreased CBF, and/or if the patient developed symp-
tomatic CVS. Contraindications to initiate Triple H therapy 
were heart failure, valvular heart disease, symptomatic coro-
nary heart disease, cardiac arrhythmias, and aortic aneurysms. 
Triple H therapy was executed using a new system to monitor 
systemic hemodynamics (PICCO Pulsion Medical Systems, 
Munich) (30). Thermodilution measurements with calibration 
of cardiac index (CI) and determination of global enddiastolic 
volume index, intrathoracic blood volume index (ITBVI) and 
extravascular lung water index (EVLWI) were performed 
every 6 hours. In addition to the conventional parameters 
(mean arterial pressure [MAP] > 105 mmHg, central venous 
pressure (CVP) 8–12 mmHg, and hematocrit 28–32%), Triple H 
therapy was adapted to the following target values: CI greater 
than 4 L/(minute • m2), ITBVI 900–1000 mL/m2, and EVLWI 
less than 10 mL/kg. Triple H therapy was induced by admin-
istration of crystalloid and colloid infusions. Dobutamine and 
norepinephrine were adjusted to maximize cardiac function. 
Excessive natriuresis and diuresis (osmolarity in urine > os-
molarity in serum, sodium in serum < 140 mmol/L) in combi-
nation with a negative fluid balance and signs of intravascular 
volume depletion were inhibited with fludrocortisone 0.2 mg/
day (31,32). Excessive water diuresis (osmolarity in urine < os-
molarity in serum, sodium in serum > 140 mmol/L) was 
treated with desmopressine 1–4 × 2 µg i.v. per day.
Endovascular Treatment
If patients with DIND did not improve or worsened despite 
Triple H therapy, digital subtraction angiography and endo-
vascular treatment with percutaneous balloon angioplasty 
and/or superselective papaverine infusion (total dose of 300 
mg) into the vasospastic vessels were performed (22,33). 
Contraindications for endovascular treatment were the pres-
ence of incompletely clipped aneurysms, ischemic infarctions, 
or a space-occupying brain edema in CT.
Barbiturate Coma, Hypothermia
Symptomatic CVS (resistant to the previously mentioned 
treatment or reoccurring after two to three spasmolysis 
 sessions) was treated with barbiturate coma and/or hypother-
mia (target brain temperature 33°C). Barbiturate coma with 
thiopental (loading dose of 5–10 mg/kg BW, followed by 
 continuous infusion) was induced at the same time as induc-
tion of hypothermia and was adapted to a burst suppression 
pattern in continuous EEG monitoring (7). Patients were ex-
cluded if they initially suffered from congestive heart failure, 
neurogenic pulmonary edema, severe aspiration pneumonia, 
other infections, or Raynaud’s phenomenon. If specific contra-
indications for thiopental were present, such as liver failure, 
hyperkaliemia (serum potassium > 4.8 mmol/L), or hyperna-
triemia (serum sodium > 150 mmol/L), only hypothermia was 
performed. Barbiturate coma and hypothermia were contin-
ued until signs of CVS decreased. Barbiturate coma and hypo-
thermia were terminated earlier if signs of severe infection, 
cardiovascular instability (arrhythmias, signs of myocardial 
ischemia, or in case of norepinephrine, dose > 50 µg/minute), 
liver failure (barbiturate coma), severe electrolyte disturbances 
(barbiturate coma), or coagulation disorders (hypothermia) 
were observed.
Outcome Measurements
Neurological outcome was assessed after 3 and 12 months 
in the outpatient clinic by a neurologist using the Glasgow Out-
come Score (GOS) (34). Those patients who did not show up 
for control were contacted and asked about their functional 
status.
Statistical Analysis
Statistical calculations were carried out using the Mann-
Whitney test (patient characteristics) and two-tailed Fisher’s 
exact test (severity grade and outcome of patients).
Results
Between January 1999 and December 2003, 210 patients 
with aSAH were treated within 3 days. A group of 12 patients 
were treated with aneurysm coiling and therefore excluded 
from the analysis. The remaining 198 patients treated with 
 microsurgical techniques were analyzed. Patient characteristics 
and the distribution of aneurysms are given in Table 2. There 
were no statistical significant differences between the two 
Table 2 
Patient Characteristics and Localization of Aneurysms
 Series 1993–1994
(n = 150) (2)
Series 1999–2003
(n = 198)
Age; mean (SD) 49.5 (12.5) 52.2 (13.3)
Gender
 Male 46 (30.7%) 54 (27.3%)
 Female 104 (69.3%) 144 (72.7%)
Timing of surgery
 Day 0
103 (68.7%)
45 (22.7%)
 Day 1 107 (54.0%)
 Day 2 31 (15.7%)
 Day 3 15 (7.6%)
Localization of ruptured 
 aneurysms
 ICA (-OphA, -PcomA, -
 AchorA, -bifurcation)
44 52
 AcomA 60 72
 Distal ACA 2 11
 MCA 35 43
 BA (head, -SCA, trunk) 6 12
 VA-PICA 3 7
 C1 0 1
n, number; SD, standard deviation; GCS, Glasgow Coma Scale; 
ICA, internal carotid artery; OphA, ophthalmic artery; PcomA, poste-
rior communicating artery; AchorA, anterior choreoidal artery; 
AcomA, anterior communicating artery; ACA, anterior cerebral artery; 
MCA, middle cerebral artery; BA, basilar artery; SCA, superior cere-
bellar artery; VA, vertebral artery; PICA, posterior inferior cerebellar 
artery; C1, cervical trunk artery.
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 patient series according to age, sex, and localization of rup-
tured aneurysms. Table 3 shows the severity of aSAH. Ac-
cording to the Hunt & Hess grading scale, 76 patients (38.4%) 
suffered from severe grades 4 and 5; whereas according to the 
WFNS grading scale, 93 (47%) patients suffered from severe 
grades 4 and 5; and the Fisher grading scale defined 162 (81.8%) 
as suffering from grades 3 and 4. Figure 1 gives the severity of 
aSAH of the patient series from 1999 to 2003, compared to the 
former series (1993 to 1994) (2). The percentage of severe aSAH 
WFNS grade 4 increased from 15.3 to 18.2% and the percentage 
of patients with WFNS grade 5 undergoing aneurysm clipping 
and special neurocritical care increased from 0 to 28.8%. During 
the period from 1999 to 2003, significantly more patients with 
most severe aSAH WFNS grade 4 and 5 underwent treatment 
(93 from 198 patients; 47.0%) compared to 23 out of 150 pa-
tients; 15.3% (p < 0.0001) during the earlier period (1993–1994). 
Table 4 gives the characteristics of treatment. With the high 
proportion of patients with poor-grade aSAH, the incidence of 
severe brain edema with elevated ICP despite osmotherapy, 
THAM, and mild hyperventilation reached a relatively high 
15.7%. All of these patients were treated with hypothermia 
combined with barbiturate coma or (because of contraindica-
tions to barbiturates) with hypothermia only. Because of refrac-
tory intracranial hypertension, 16 patients (8.1%) were treated 
with secondary decompressive surgery.
CVS occurred in 39.9% of the cases. Out of 79 patients with 
symptomatic CVS, 78 were treated with Triple H therapy and 
33 with balloon angioplasty and/or intraarterial papaverine 
instillation. A group of 23 patients with CVS refractory to 
Triple H therapy and spasmolysis were treated with hypother-
mia combined with barbiturate coma or (because of contrain-
dications to barbiturates) with hypothermia only. In the patient 
series of 1993 to 1994, two patients with CVS refractory to 
Triple H therapy and spasmolysis were treated with barbitu-
rate coma (2). No hypothermia treatment was performed dur-
ing the earlier period.
Table 3 
Severity of aSAH
 Series 1999–2003 (n = 198)
Hunt & Hess Grading
 H & H Grade 1 14 (7.1%)
 H & H Grade 2 65 (32.8%)
 H & H Grade 3 43 (21.7%)
 H & H Grade 4 47 (23.7%)
 H & H Grade 5 29 (14.7%)
WFNS Grading
 WFNS Grade 1 50 (25.2%)
 WFNS Grade 2 40 (20.2%)
 WFNS Grade 3 15 (7.6%)
 WFNS Grade 4 36 (18.2%)
 WFNS Grade 5 57 (28.8%)
Fisher Grading
 Fisher Grade 1 4 (2.0%)
 Fisher Grade 2 32 (16.2%)
 Fisher Grade 3 72 (36.4%)
 Fisher Grade 4 90 (45.4%)
aSAH, aneurysmal subarachnoid hemorrhage; n, number; H & H, 
Hunt and Hess; WFNS, World Federation of Neurological Surgeons.
Fig. 1. Severity of aneurysmal subarachnoid hermorrhage. Comparison between patient series 1993–1994 (after introduction of early 
 surgery) (2) and 1999–2003 (after introduction of structured neruointensive care). In the time period 1993–1994 (2) patients with WFNS 
grade 5 aSAH were not treated with aneurysm surgery. The percentage of patients with poor grade aSAH WFNS 4 and 5 increased from 
15.3% (in the earlier series) to 47% (in the later series), whereas the percentage of patients with WFNS 1 and 2 aSAH decreased from 
57.4 to 45.4%.
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In 36.9% of the cases, shunt dependency from malresorp-
tive hydrocephalus occurred. All but four out of 73 patients 
treated with ventriculoperitoneal shunt suffered from Fisher 
grades 3 and 4. Their mean age (59.7 ± 10.1 years) tended to be 
higher compared to the whole population.
The results of the patient series 1999 to 2003 are given in 
Table 5. Compared to the earlier series, the overall outcome 
didn’t change. Between 1999 and 2003, 131 patients (66.1%) 
survived with good functional outcome GOS 4 and 5, respec-
tively, after 3 months and 142 (71.7%) after 12 months. Whereas 
between 1993 and 1994, 112 out of 150 (75%) survived with 
GOS 4 and 5 after 3 months (2). Table 6 shows the outcome of 
the patient subgroup with poor-grade aSAH WFNS 4 and 5 in 
the series of 1999 to 2003. The analysis of the patient series 
from 1993 to 1994 does not include any patients with WFNS 
grade 5. Special treatment not being available before 1999, pa-
tients with WFNS grade 5 died or survived in a vegetative 
state. Therefore, only the outcome of patients with severe 
aSAH WFNS grade 4 can be compared between the two series. 
In the early series of 1993 to 1994, 10 out of 23 patients (43.5%) 
with WFNS 4 aSAH recovered with good functional outcome 
(2), whereas in the series between 1999 and 2003, 23 out of 36 
patients (63.9%) with WFNS grade 4 survived in a good func-
tional state after 3 months (without statistical significance). In 
the later series (from 1999 to 2003), 57 patients (28.8%) suffered 
from most-severe aSAH WFNS grade 5. Of these, 20 (35.1%) 
survived with good functional outcome after 12 months (21.1% 
with GOS 5 and 14% with GOS 4).
Discussion
In recent years, increased experience in neurosurgical tech-
niques and the possibility of endovascular coiling made it pos-
sible to address patients with most severe aSAH and to exclude 
aneurysms in the acute stage of “angry brain” (2,35,36). These 
patients, however, suffer from a high incidence of specific 
complications such as severe brain edema with refractory ICP 
elevations and symptomatic CVS. In the later series, 47% of the 
patients suffered from severe aSAH WFNS 4 and 5. Because of 
the high percentage of patients with Fisher grade 3 and 4 
bleedings, the incidence of symptomatic CVS reached a high 
40%. With 36.9% compared to 9%, the number of cases of shunt 
dependency from malresorptive hydrocephalus was higher in 
the later series than in the early series (2). However, surgical 
techniques (extensively opening of the lamina terminals and 
membrane of Liliequist, avoiding the use of continuous drain-
age if possible) did not change in the meantime. The higher 
shunt dependency in the present series might be explained by 
the higher percentage of patients with severe aSAH and the 
more frequently used ventricular catheters in order to monitor 
ICP and to perform and control CSF drainage (37).
Therefore, to obtain good results (especially in patients 
with high-grade aSAH), not only the prevention of rebleeding 
by performing early surgery as well as avoiding technical op-
erative complications, but also standardized protocols for spe-
cialized neurocritical care are of great importance. The main 
Table 4 
Characteristics of Treatment
 Series 1999–2003
(n = 198)
Incidence of ICP > 15 mmHg despite 
 osmotherapy, THAM, and mild 
 hyperventilation
31 (15.7%)
 Treated with hypothermia combined 
 with barbiturate coma
29 (14.6%)
 Treated with hypothermia only 2 (1.0%)
 Treated with secondary decompressive 
 surgery
16 (8.1%)
Incidence of symptomatic CVS 79 (39.9%)
 Treated with Triple H therapy 78 (39.4%)
 Treated with spasmolysis 33 (16.7%)
  Once 26 (13.1%)
  Twice 5 (2.5%)
  Three times 2 (1.0%)
Treated with hypothermia 
combined with barbiturate coma
23 (11.6%)
Treated with hypothermia only 3 (1.5%)
Incidence of malresorptive hydrocephalus 
 treated with VP shunt
73 (36.9%)
n, number; ICP, intracranial pressure; THAM, trishydroxyamino-
methan buffer; CVS, cerebral vasospsm; Triple H, hypertensive hyper-
volemic hemodilution; VP, ventriculoperitoneal.
Table 5 
Outcome of Patients
Series 1999–2003
(n = 198)
Glasgow Outcome Scale 3 months after 
aSAH
12 months after 
aSAH
GOS 5 88 (44.4%) 115 (58.1%)
GOS 4 43 (21.7%) 27 (13.6%)
GOS 3 36 (18.2%) 28 (14.2%)
GOS 2 13 (6.6%) 1 (0.5%)
GOS 1 18 (9.1%) 27 (13.6%)
Died of CVS 7 (3.5%)
Permanent additional 
deficits caused by CVS
17 (8.6%)
n, number; aSAH, aneurysmal subarachnoid hemorrhage; GOS, 
Glasgow Outcome Scale; CVS, cerebral vasospasm.
Table 6 
Outcome of Patients Suffering From Poor-Grade aSAH 
WFNS 4 and 5
 Series 1999–2003 
(n = 92)
Glasgow Outcome Scale 3 months after 
aSAH
12 months after 
aSAH
GOS 5 24 (26.1%) 36 (39.1%)
GOS 4 20 (21.7%) 14 (15.2%)
GOS 3 22 (23.9%) 21 (22.8%)
GOS 2 12 (13.1%) 1 (1.1%)
GOS 1 14 (15.2%) 20 (21.8%)
aSAH, aneurysmal subarachnoid hemorrhage; WFNS, World Fed-
eration of Neurological Surgeons; n, number; GOS, Glasgow Outcome 
Scale.
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features of a structured neurocritical care treatment approach 
are: (1) emergency therapy of the acute ICP crisis and cardio-
vascular stabilization before surgery (neurorescucitation); (2) 
postoperative treatment of brain edema and elevated ICP; and 
(3) prophylaxis, detection, and treatment of possible CVS and 
4, and treatment of medical complications.
Comparisons with historical patient series, not adjusting 
for patient and treatment characteristics, have major limita-
tions. This report, however, is focused on the evaluation of the 
impact of specialized neurocritical care treatment. It is beyond 
the scope of the study to examine the influence of aneurysm 
coiling on the outcome of the patients. Therefore, patients 
treated with coiling were excluded from the analysis. Principles 
of microsurgical techniques didn’t change between 1993 and 
2003. During both periods, more than 90% of the operations 
were performed by the second author (Y.Y.) applying the 
 standard microsurgical technique described by Yasargil (1). 
Therefore, the study shows clearly some trends and may serve 
as a guide for future planning with regards to resources in 
neurocritical care.
Over the years, a change in the patient population to-
wards a higher severity grade occurred in our specialized 
neurovascular center. On the one hand, the shift within the 
admitted patient population may be caused by changes in 
national health policy aspects. On the other hand, it may be 
owing to the fact that the availability of extended resources 
for neurorescucitation, early aneurysm surgery, and special-
ized neurocritical care becomes common knowledge among 
referring institutions and may lead to different admission 
policies.
In the period between 1993 and 1994, patients with WFNS 
grade 5 didn’t undergo special treatment (2). Therefore, in the 
early years, patients with WFNS grade 5 died or survived in a 
vegetative state. In 1999, the previously listed standards for 
emergency neurorescucitation and postoperative neurocritical 
care were established in our neurocritical care unit. If, in pa-
tients with aSAH WFNS grade 5, pupil disturbances normal-
ized after emergency treatment, they consequently underwent 
early aneurysm clipping and, after surgery, were treated 
against severe brain edema and CVS in the neurocritical care 
unit. In recent years, in more than one-third of these patients 
with aSAH WFNS grade 5 a good functional outcome could be 
obtained, and in the group with most severe aSAH WFNS 
grade 4 and 5, even more than 50% of the cases showed a good 
functional outcome. Furthermore, the proportion of patients 
with aSAH WFNS grade 4 surviving in a good functional state 
after 3 months tended to increase from 43.5% in the earlier se-
ries to 63.9% in the later series. This might suggest that pa-
tients with most-severe aSAH, suffering from massive brain 
edema and prolonged ICP elevations, as well as those with in-
tractable CVS may benefit most from highly specialized neur-
ocritical treatment. Indeed, recent studies demonstrated that 
patients with severe head injury, ischemic stroke, and intrace-
rebral hemorrhage benefit from specialized neurocritical care 
and stroke units (38–40). Specialized knowledge of elaborate 
diagnostic procedures is particularly required in patients with 
aSAH. Complex treatment strategies applied in these patients 
(e.g., long-term hypothermia) call for experienced medical and 
nursing staff, especially trained in neurocritical care topics. 
Not only do the expensive technical equipment for specialized 
neuromonitoring, neuroimaging, and extended monitoring of 
cerebral and systemic hemodynamics have to be available, but 
most of all optimal interdisciplinary collaboration between 
neurosurgeons, neuoradiologists, and neurointensivists is re-
quired (41). In many neurocenters, specialized neurocritical 
care units serve as the focal point for these combined efforts 
(42,43).
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